Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC)

por Wang, Wenguang, Gan, Zhilu, Liu, Qiang, Yan, Shenshen, Mulati, Rexiti, Wang, Yujie
Publicado 2021